碳酸氢钠林格液在创伤性失血性休克早期复苏中的有效性和安全性观察:一项单中心前瞻性随机对照临床试验
本研究为单中心前瞻性随机对照试验,计划纳入400例成人创伤性失血性休克患者,按1:1随机分组,在标准治疗基础上分别接受碳酸氢钠林格液(试验组)或乳酸钠林格液(对照组)复苏至成功。主要终点为给药后0.5、1、1.5、3、6小时的乳酸清除率及休克持续时间,次要终点包括凝血功能、体温、酸中毒、炎症介质水平、休克复发、并发症、用药及7天死亡率,随访至出院或出院后7天。
要点
- 碳酸氢钠林格液含碳酸氢钠、电解质及渗透压更接近血浆。
- 主要终点为不同时间点乳酸清除率和给药后休克持续时间。
- 次要终点包括凝血功能、体温、酸中毒、炎症介质、休克复发、并发症、用药及7天死亡率。
核心结论
- 本试验旨在为创伤性失血性休克患者的复苏液体选择及碳酸氢钠林格液安全剂量探索提供重要临床数据。
研究设计与样本
- 单中心、前瞻性、随机对照试验,计划纳入400例成人创伤性失血性休克患者。
- 在标准治疗基础上按1:1随机分为碳酸氢钠林格液组(试验组)和乳酸钠林格液组(对照组),复苏至成功。
- 随访至出院或出院后7天。
- 试验注册于中国临床试验注册中心(ChiCTR),注册号ChiCTR2100045044,注册日期2021年4月4日。
主要发现
- 原文为试验方案,尚未报告结果。
关键数值与推荐
- 主要终点:给药后0.5、1、1.5、3、6小时的乳酸清除率及给药后休克持续时间。
- 次要终点:凝血功能、体温、酸中毒、炎症介质水平、休克复发、并发症、用药及7天死亡率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Traumatic hemorrhagic shock (THS) is the main cause of death in trauma patients with high mortality. Rapid control of the source of bleeding and early resuscitation are crucial to clinical treatment. Guidelines recommend isotonic crystal resuscitation when blood products are not immediately available. However, the selection of isotonic crystals has been controversial. Sodium bicarbonate Ringer solutions (BRS), containing sodium bicarbonate, electrolyte levels, and osmotic pressures closer to plasma, are ideal. Therefore, in this study, we will focus on the effects of BRS on the first 6 h of resuscitation, complications, and 7-day survival in patients with THS. METHODS: /design. This single-center, prospective, randomized controlled trial will focus on the efficacy and safety of BRS in early THS resuscitation. A total of 400 adults THS patients will be enrolled in this study. In addition to providing standard care, enrolled patients will be randomized in a 1:1 ratio to receive resuscitation with BRS (test group) or sodium lactate Ringer's solution (control group) until successful resuscitation from THS. Lactate clearance at different time points (0.5, 1, 1.5, 3, and 6 h) and shock duration after drug administration will be compared between the two groups as primary end points. Secondary end points will compare coagulation function, temperature, acidosis, inflammatory mediator levels, recurrence of shock, complications, medication use, and 7-day mortality between the two groups. Patients will be followed up until discharge or 7 days after discharge. DISCUSSION: At present, there are still great differences in the selection of resuscitation fluids, and there is a lack of systematic and detailed studies to compare and observe the effects of various resuscitation fluids on the effectiveness and safety of early resuscitation in THS patients. This trial will provide important clinical data for resuscitation fluid selection and exploration of safe dose of BRS in THS patients. TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR), ChiCTR2100045044. Registered on 4 April 2021.
引用
- Zhang J, Han D, Zhang K, et al. Observation on the effectiveness and safety of sodium bicarbonate Ringer's solution in the early resuscitation of traumatic hemorrhagic shock: a clinical single-center prospective randomized controlled trial. Trials. 2022. PMID: 36175936. doi:10.1186/s13063-022-06752-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。